Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: AbbVie Ltd., Maidenhead, SL6 4UB, UK
Ocufen is indicated for:
For the inhibition of intraoperative miosis, 1 drop is instilled every half hour starting 2 hours before surgery. The final drop should be given not less than 30 minutes before surgery.
To control post-operative and post-laser trabeculoplasty inflammation the dosing regimen above should be followed. Beginning twenty-four hours after surgery, one drop is administered four times daily for at least one week after laser trabeculoplasty or for two to three weeks after other surgery.
The safety and efficacy of Ocufen in children has not been established.
There is no specific advice for the elderly.
Ocufen is administered topically by instillation into the conjunctival sac.
In accordance with standard practice, other topical medication should not be co-administered with Ocufen. When administering other topical medications, a minimum interval of 5 minutes between instillations is recommended.
Overdose by the topical ophthalmic route will not ordinarily cause acute problems. If accidentally ingested, treatment should be symptomatic.
The shelf life is 24 months for the unopened vial. The vial should be discarded after a single dose. The remaining vials should be placed back in the original pouch after each use.
Store at or below 25°C.
Clear, plastic unit dose vial, each containing 0.4 ml of solution.
Each vial of Ocufen should be used for a single dose and discarded after use.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.